266 related articles for article (PubMed ID: 1510710)
1. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
4. High yield expression of functionally active human liver CYP2D6 in yeast cells.
Krynetski EY; Drutsa VL; Kovaleva IE; Luzikov VN
Pharmacogenetics; 1995 Apr; 5(2):103-9. PubMed ID: 7663527
[TBL] [Abstract][Full Text] [Related]
5. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
6. The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae.
Ching MS; Lennard MS; Tucker GT; Woods HF; Kelly DE; Kelly SL
Biochem Pharmacol; 1991 Jul; 42(4):753-8. PubMed ID: 1867632
[TBL] [Abstract][Full Text] [Related]
7. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
Haritos VS; Ching MS; Ghabrial H; Gross AS; Taavitsainen P; Pelkonen O; Battaglia SE; Smallwood RA; Ahokas JT
Pharmacogenetics; 1998 Oct; 8(5):423-32. PubMed ID: 9825834
[TBL] [Abstract][Full Text] [Related]
9. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
10. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
Jang GR; Wrighton SA; Benet LZ
Biochem Pharmacol; 1996 Sep; 52(5):753-61. PubMed ID: 8765473
[TBL] [Abstract][Full Text] [Related]
11. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
12. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.
Crespi CL; Steimel DT; Penman BW; Korzekwa KR; Fernandez-Salguero P; Buters JT; Gelboin HV; Gonzalez FJ; Idle JR; Daly AK
Pharmacogenetics; 1995 Aug; 5(4):234-43. PubMed ID: 8528270
[TBL] [Abstract][Full Text] [Related]
13. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae.
Brian WR; Sari MA; Iwasaki M; Shimada T; Kaminsky LS; Guengerich FP
Biochemistry; 1990 Dec; 29(51):11280-92. PubMed ID: 2271712
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
15. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae.
Brian WR; Srivastava PK; Umbenhauer DR; Lloyd RS; Guengerich FP
Biochemistry; 1989 Jun; 28(12):4993-9. PubMed ID: 2669966
[TBL] [Abstract][Full Text] [Related]
16. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
[TBL] [Abstract][Full Text] [Related]
17. Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme.
Renaud JP; Cullin C; Pompon D; Beaune P; Mansuy D
Eur J Biochem; 1990 Dec; 194(3):889-96. PubMed ID: 2269307
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
19. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
20. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
